Spanish study group on cochlear implants for persons with marginal benefit from acoustic amplification

Area of Science:

• Audiology
• Otorhinolaryngology
• Biomedical Engineering

Background:

• The U.S. FDA approved cochlear implants (CI) for severe-to-profound sensorineural hearing loss patients with limited hearing aid (HA) benefit.
• A multicenter trial was conducted to assess CI efficacy in the Spanish population.

Purpose of the Study:

• To evaluate the effectiveness of cochlear implants (CI) in postlingual adults with severe-to-profound hearing loss in Spain.
• To compare speech recognition performance with hearing aids (HA) versus cochlear implants (CI).

Main Methods:

• Nine postlingual adults with severe-to-profound hearing loss participated.
• A single-subject design compared pre-operative HA use with post-operative CI use.
• Pure-tone average (PTA) thresholds and Spanish open-set speech recognition tests were administered.

Main Results:

• All subjects showed significant improvements in aided soundfield thresholds and speech recognition after 6 months of CI use.
• Mean bisyllabic recognition increased from 20% to 57%, consonant discrimination from 20% to 49%, and CID sentence recognition from 22% to 73%.
• Most subjects (8/9) reduced or discontinued HA use post-implantation, indicating CI preference.

Conclusions:

• Cochlear implantation (CI) is an effective treatment for Spanish patients with severe-to-profound hearing loss and marginal benefit from hearing aids (HA).
• CI significantly enhances speech understanding compared to the best pre-implant HA performance.